Merus shares are trading higher after the FDA granted Breakthrough Therapy Designation to zenocutuzumab for the treatment of NRG1+ pancreatic cancer.
Portfolio Pulse from Benzinga Newsdesk
Merus shares are trading higher after the FDA granted Breakthrough Therapy Designation to zenocutuzumab for the treatment of NRG1+ pancreatic cancer.
June 29, 2023 | 8:32 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Merus shares are trading higher after the FDA granted Breakthrough Therapy Designation to its drug zenocutuzumab for the treatment of NRG1+ pancreatic cancer.
The FDA's Breakthrough Therapy Designation is given to drugs that may offer significant benefits over existing options. This designation for Merus' zenocutuzumab indicates a positive outlook for the drug's development and potential market success, which is likely driving the increase in Merus' share price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100